Management of hypertension in solid-organ transplantation.
Posttransplant hypertension is a major risk factor for cardiovascular disease and chronic renal allograft dysfunction. A significant number of transplant recipients suffer from posttransplant hypertension in part because of corticosteroid and calcineurin inhibitor use. Although the optimal blood pressure range and the antihypertensive agents of choice in the transplant population have not been determined, the guidelines for blood pressure control in the general population can be extrapolated to the transplant population. The choice of an antihypertensive regimen should be tailored on the basis of the individual patient's risk factors and comorbidities.
Park
Jeong M
JM
University of Michigan, Ann Arbor, MI, USA.
Luan
Fu L
FL
D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000209:etiology; D016377:Organ Transplantation / Q000009:adverse effects*
D000959:Antihypertensive Agents